Navigation Links
HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Date:9/12/2011

SAN DIEGO, Sept. 12, 2011 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease. The study, initiated in April of this year, enrolled a total of 52 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon, and is designed to evaluate the safety and tolerability of HQK-1001. Secondary objectives include the effect on fetal hemoglobin and sickle cell crises. HemaQuest expects interim results from the study in late 2011 and final results in the first quarter of 2012.

"To complete enrollment in just five months is a significant accomplishment and a credit to everyone involved in the trial," said HemaQuest Chief Medical Officer Richard G. Ghalie, MD. "We believe that the rapid enrollment demonstrates the need for, as well as the excitement among physicians treating sickle cell disease worldwide about, a potential new therapy for this devastating disease which affects underserved populations around the world."

ABOUT HQK-1001 HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia.  Increased fetal hemoglobin production in red blood cells has been shown to reduce the frequency of pain crises and hospitalizations of patients with sickle cell disease.  HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevan
'/>"/>

SOURCE HemaQuest Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
2. HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
3. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
4. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
5. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
6. AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
7. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
8. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
9. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
10. Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 This report ... Million by the following Product Categories: Enteral Feeding Pumps, Nasogastric ... analytics for the US Canada, Japan , ... Latin America , and Rest of World. ... through 2018. Also, a six-year historic analysis is provided for ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... natural way to modernize medicine, announced today the ... line of nutraceuticals developed to address men and ... staying healthy and vibrant into old age while ... line includes three condition-specific, whole-food and herb-based formulas, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... (Ulleval,University Hospital, Oslo, Norway), lead investigator for the ... provide an update on,the study on Monday the ... be Sir Richard Peto (Professor of Medical,Statistics and ... University of Oxford) Professor Rory Collins (BHF Professor ...
... NEW YORK, July 17 The Michael J. ... in total funding to nine research teams under ... intellectual and financial,resources to help push potential PD ... nearly five million Parkinson,s patients,worldwide., "The discovery ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease 2Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease 3
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining how ... Senior citizens can qualify for affordable term life insurance ... are over 50 years old. Some term life insurance ... , Term life insurance with a simplified issue can ... life insurance during retirement is important for covering funeral ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... say on whether patients should have to opt in or ... is concerned that, in the proposed summary care record, data ... and this is not being made sufficiently clear to the ... letter to this week's journal. ,"Patients and clinicians ...
... care workers in the United States has risen, so ... ,According to Vanderbilt infectious disease experts Timothy ... should be provided to health care workers with latent ... test, particularly if they meet certain high-risk criteria. ...
... the debate with many others to discuss on the focus ... women.// Instead of giving a conceptual argument on the similarities ... and proved. ,Barres' experience as a female-to-male transgendered ... July 13 issue of Nature rebuking the comments of former ...
... A study led by Australian researchers has discovered a ... binding protein in human airway epithelial cells// that regulates ... researchers had explained in their study that the adipocyte/macrophage ... the uptake by fat cells of fatty acids and ...
... suicide fail to seek help from a doctor or mental ... may find it difficult to obtain adequate// treatment or medication, ... improve access to treatment for people with suicide ideation," said ... Los Angeles and study co-author. "There is a problem with ...
... published in the open access journal Substance Abuse Treatment, Prevention ... regular extra// training treats the alcohol dependent patients better for ... patients treated by trained GPs who abstain from drinking alcohol ... received the basic training alone at the medical school. ...
Cached Medicine News:Health News:Electronic Patient Record "Serious Threat" to Patient Confidentiality 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 2Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 3Health News:Transgender Experience - A Tool to Analyze Gender Difference By Stanford Scientist 4Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Many Suicidal Adults Aren't Getting Mental Health Treatment 2
Dust covers for a variety of Zeiss microscopes...
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark...
... Axiovert 40 inverted ... you have ever expected from a microscope in ... outstanding quality, and functionality. Axiovert 40 has been ... safe as possible thus increasing the efficiency ...
... TE2000E is an advanced inverted microscope for ... imaging ports, high resolution CFI60 optics, and ... imaging workstation. In addition, its super-nanoprecision z-axis ... is perfect for precise imaging in 3D. ...
Medicine Products: